Mesenchymal cell proliferation and programmed cell death: key players in fibrogenesis and new targets for therapeutic intervention
- PMID: 21233275
- DOI: 10.1152/ajpgi.00504.2010
Mesenchymal cell proliferation and programmed cell death: key players in fibrogenesis and new targets for therapeutic intervention
Abstract
An exquisite equilibrium between cell proliferation and programmed cell death is required to maintain physiological homeostasis. In inflammatory bowel disease, and especially in Crohn's disease, enhanced proliferation along with defective apoptosis of immune cells are considered key elements of pathogenesis. Despite the relatively limited attention that has been given to research efforts devoted to intestinal fibrosis to date, there is evidence suggesting that enhanced proliferation along with defective programmed cell death of mesenchymal cells can significantly contribute to the development of excessive fibrogenesis in many different tissues. Moreover, some therapies have demonstrated potential antifibrogenic efficacy through the regulation of mesenchymal cell proliferation and programmed cell death. Further understanding of the pathways involved in the regulation of mesenchymal cell proliferation and apoptosis is, however, required.
Similar articles
-
Fibrogenesis in Crohn's disease.Am J Gastroenterol. 2007 Feb;102(2):439-48. doi: 10.1111/j.1572-0241.2006.01010.x. Epub 2006 Dec 11. Am J Gastroenterol. 2007. PMID: 17156147 Review.
-
Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses.Gastroenterology. 2009 Mar;136(3):978-89. doi: 10.1053/j.gastro.2008.11.041. Epub 2008 Nov 27. Gastroenterology. 2009. PMID: 19135996
-
RB and RB2/p130 genes demonstrate both specific and overlapping functions during the early steps of in vitro neural differentiation of marrow stromal stem cells.Cell Death Differ. 2005 Jan;12(1):65-77. doi: 10.1038/sj.cdd.4401499. Cell Death Differ. 2005. PMID: 15459751
-
Stem cell treatment for Crohn's disease.Expert Rev Clin Immunol. 2010 Jul;6(4):597-605. doi: 10.1586/eci.10.27. Expert Rev Clin Immunol. 2010. PMID: 20594133
-
Mechanisms involved in the therapeutic properties of mesenchymal stem cells.Cytokine Growth Factor Rev. 2009 Oct-Dec;20(5-6):419-27. doi: 10.1016/j.cytogfr.2009.10.002. Epub 2009 Nov 18. Cytokine Growth Factor Rev. 2009. PMID: 19926330 Review.
Cited by
-
The Molecular Mechanism of Transforming Growth Factor-β Signaling for Intestinal Fibrosis: A Mini-Review.Front Pharmacol. 2019 Feb 27;10:162. doi: 10.3389/fphar.2019.00162. eCollection 2019. Front Pharmacol. 2019. PMID: 30873033 Free PMC article. Review.
-
Prostaglandin E₂ and polyenylphosphatidylcholine protect against intestinal fibrosis and regulate myofibroblast function.Dig Dis Sci. 2015 Jun;60(6):1603-16. doi: 10.1007/s10620-015-3552-9. Epub 2015 Jan 29. Dig Dis Sci. 2015. PMID: 25630423
-
Cellular and Molecular Mediators of Intestinal Fibrosis.J Crohns Colitis. 2017 Dec 4;11(12):1491-1503. doi: 10.1016/j.crohns.2014.09.008. J Crohns Colitis. 2017. PMID: 25306501 Free PMC article. Review.
-
Pirfenidone suppresses TGF‑β1‑induced human intestinal fibroblasts activities by regulating proliferation and apoptosis via the inhibition of the Smad and PI3K/AKT signaling pathway.Mol Med Rep. 2018 Oct;18(4):3907-3913. doi: 10.3892/mmr.2018.9423. Epub 2018 Aug 22. Mol Med Rep. 2018. PMID: 30152848 Free PMC article.
-
Fibrostenosing Crohn's Disease: Pathogenetic Mechanisms and New Therapeutic Horizons.Int J Mol Sci. 2024 Jun 7;25(12):6326. doi: 10.3390/ijms25126326. Int J Mol Sci. 2024. PMID: 38928032 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources